Sign In
Buy ATOS
$0.785
-0.0150 (-1.88%)
At Close: Nov 17, 2025
Published article outlines rationale for multi-pathway efficacy for (Z)-endoxifen in Duchenne Muscular Dystrophy (DMD); November scientific presentation to spotlight potential in Duchenne carrier–as
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
08:15am, Wednesday, 12'th Nov 2025
Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities, including a Type C meeting wit
Studies highlight findings in the use of (Z)-endoxifen to advance breast cancer treatment and prevention SEATTLE , Nov. 6, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or t
New Strong Sell Stocks for Oct. 22
07:36am, Wednesday, 22'nd Oct 2025
ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.
Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk development of (Z)-Endoxifen and other endocrine therapies for DCIS SEATTLE
Atossa Therapeutics to Present at the Maxim Growth Summit 2025
08:00am, Wednesday, 15'th Oct 2025
Invites New Investors to Learn More About $ATOS SEATTLE , Oct. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
08:00am, Tuesday, 14'th Oct 2025
25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen SEATTLE
New Strong Sell Stocks for Oct. 14th
07:10am, Tuesday, 14'th Oct 2025
AR, BTCS and ATOS have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2025.
Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
08:00am, Monday, 13'th Oct 2025
Portfolio covers high-purity Z-endoxifen enteric formulations, performance characteristics, and manufacturing methods, part of Atossa's multi-jurisdiction IP strategy to support clinical and commercia
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
08:00am, Monday, 06'th Oct 2025
Changes are expected to reduce future study costs, accelerate objective readouts, and extend operating runway under current plans SEATTLE , Oct. 6, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nas
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
08:30am, Wednesday, 01'st Oct 2025
Veteran development leader with successful regulatory approvals record returns to lead late-stage clinical and regulatory programs to address multiple unmet clinical needs SEATTLE , Oct. 1, 2025 /PRNe
Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
08:00am, Wednesday, 17'th Sep 2025
SEATTLE, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; “Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing new approaches in breast
Type C FDA Meeting Requested, Update Expected by Year-End 2025 SEATTLE , Sept. 8, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has reques
Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference
08:30am, Thursday, 28'th Aug 2025
Dr. Steven Quay, Chairman and Chief Executive Officer to participate in Fireside Chat with Emily Bodnar, HCW Biotech Research Analyst SEATTLE , Aug. 28, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc.
Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025 Topline results anticipated in 2026 Positions Atossa for transition into registrational Phase 3 development SEATTLE , Aug.
